Edwards Lifesciences Corp (EW) Company Profile

Edwards Lifesciences Corp is a medical device company that specializes in developing and manufacturing products for structural heart disease and critical care monitoring. Its primary business is creating minimally invasive replacement heart valves, such as transcatheter aortic valve replacement (TAVR) systems, which are implanted without open-heart surgery. Its customers are hospitals and healthcare systems, and its success is driven by clinical outcomes and physician training. The company's moat is strong, scoring highly on several criteria from Section 1 of the framework. It demonstrates significant switching costs, as its valves are mission-critical and require specialized physician training, creating high migration costs. It holds proprietary data from extensive clinical trials, benefits from regulatory barriers for new entrants, and shows technology leadership as a pioneer in TAVR. Founder-led execution and pricing power, evidenced by its ability to maintain premium prices, further solidify its competitive position. However, key risks from Section 5 include potential regulatory/geopolitical risk in global markets and the ever-present competitive erosion risk as rivals develop next-generation devices. For a value investor, the primary concern is valuation. The current P/E of 44.7 is high, especially for a company with 13.3% revenue growth and a 10.4% ROE, which is below the 15-20% high-quality threshold. The GoodMoat Target of $55.68 suggests the stock may be overvalued relative to an estimated intrinsic value, indicating a lack of a sufficient margin of safety at the current price of $82.67.